Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy

Jun Ah Lee; Dae Geun Jeon; Wan Hyeong Cho; Won Seok Song; Hoi Soo Yoon; Hyeon Jin Park; Byung Kiu Park; Hyoung Soo Choi; Hyo Seop Ahn; Ji Won Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Hyoung Jin Kang; Kyung Duk Park; Hee Young Shin; Kyung Nam Koh; Ho Joon Im; Jong Jin Seo; Yeon Jung Lim; Hee Jo Baek; Hoon Kook

doi:10.1002/pbc.26058

Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy

Jun Ah Lee, Dae Geun Jeon, Wan Hyeong Cho, Won Seok Song, Hoi Soo Yoon, Hyeon Jin Park, Byung Kiu Park, Hyoung Soo Choi, Hyo Seop Ahn, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Hyoung Jin Kang, Kyung Duk Park, Hee Young Shin, Kyung Nam Koh, Ho Joon Im, Jong Jin Seo, Yeon Jung LimHee Jo Baek, Hoon Kook

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Background: Efficacy of gemcitabine and docetaxel (GEM + DOC) chemotherapy in patients with recurrent or refractory osteosarcoma was evaluated. Methods: Data of 53 patients from 9 institutions, who received GEM (675 or 900 mg/m² on days 1 and 8) and DOC (100 mg/m² on day 8), were retrospectively reviewed. Results: GEM + DOC was administered as adjuvant (n = 25) or palliative chemotherapy (n = 28). Patients received a median 3 courses (range, 1−10 courses). Objective response rate (CR + PR, where CR is complete response and PR is partial response) and disease control rate (CR+ PR + SD, where SD is stable disease) were 14.3% and 28.6%, respectively. Disease control rate was higher in patients receiving 900 mg/m² GEM than in patients receiving 675 mg/m² (50.0% vs. 12.5%, P = 0.03). Higher GEM dose was associated with better survival, both in adjuvant (1-year overall survival, 90.9 ± 8.7% vs. 38.5 ± 13.5%, P = 0.002) and palliative settings (50.0 ± 14.4% vs. 31.3 ± 11.6%, P = 0.04). Conclusions: Further studies are necessary to investigate the efficacy of more aggressive and higher doses of GEM + DOC chemotherapy in osteosarcoma.

Original language	English
Pages (from-to)	1552-1556
Number of pages	5
Journal	Pediatric Blood and Cancer
Volume	63
Issue number	9
DOIs	https://doi.org/10.1002/pbc.26058
State	Published - 1 Sep 2016
Externally published	Yes

Keywords

docetaxel
gemcitabine
osteosarcoma
recurrent
refractory

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/pbc.26058

Cite this

Lee, J. A., Jeon, D. G., Cho, W. H., Song, W. S., Yoon, H. S., Park, H. J., Park, B. K., Choi, H. S., Ahn, H. S., Lee, J. W., Yoo, K. H., Sung, K. W., Koo, H. H., Kang, H. J., Park, K. D., Shin, H. Y., Koh, K. N., Im, H. J., Seo, J. J., ... Kook, H. (2016). Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy. Pediatric Blood and Cancer, 63(9), 1552-1556. https://doi.org/10.1002/pbc.26058

@article{9fcac5b56d00483a8d0c2dd0da6d3c4d,

title = "Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy",

abstract = "Background: Efficacy of gemcitabine and docetaxel (GEM + DOC) chemotherapy in patients with recurrent or refractory osteosarcoma was evaluated. Methods: Data of 53 patients from 9 institutions, who received GEM (675 or 900 mg/m2 on days 1 and 8) and DOC (100 mg/m2 on day 8), were retrospectively reviewed. Results: GEM + DOC was administered as adjuvant (n = 25) or palliative chemotherapy (n = 28). Patients received a median 3 courses (range, 1−10 courses). Objective response rate (CR + PR, where CR is complete response and PR is partial response) and disease control rate (CR+ PR + SD, where SD is stable disease) were 14.3\% and 28.6\%, respectively. Disease control rate was higher in patients receiving 900 mg/m2 GEM than in patients receiving 675 mg/m2 (50.0\% vs. 12.5\%, P = 0.03). Higher GEM dose was associated with better survival, both in adjuvant (1-year overall survival, 90.9 ± 8.7\% vs. 38.5 ± 13.5\%, P = 0.002) and palliative settings (50.0 ± 14.4\% vs. 31.3 ± 11.6\%, P = 0.04). Conclusions: Further studies are necessary to investigate the efficacy of more aggressive and higher doses of GEM + DOC chemotherapy in osteosarcoma.",

keywords = "docetaxel, gemcitabine, osteosarcoma, recurrent, refractory",

author = "Lee, \{Jun Ah\} and Jeon, \{Dae Geun\} and Cho, \{Wan Hyeong\} and Song, \{Won Seok\} and Yoon, \{Hoi Soo\} and Park, \{Hyeon Jin\} and Park, \{Byung Kiu\} and Choi, \{Hyoung Soo\} and Ahn, \{Hyo Seop\} and Lee, \{Ji Won\} and Yoo, \{Keon Hee\} and Sung, \{Ki Woong\} and Koo, \{Hong Hoe\} and Kang, \{Hyoung Jin\} and Park, \{Kyung Duk\} and Shin, \{Hee Young\} and Koh, \{Kyung Nam\} and Im, \{Ho Joon\} and Seo, \{Jong Jin\} and Lim, \{Yeon Jung\} and Baek, \{Hee Jo\} and Hoon Kook",

note = "Publisher Copyright: {\textcopyright} 2016 Wiley Periodicals, Inc.",

year = "2016",

month = sep,

day = "1",

doi = "10.1002/pbc.26058",

language = "English",

volume = "63",

pages = "1552--1556",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "9",

}

Lee, JA, Jeon, DG, Cho, WH, Song, WS, Yoon, HS, Park, HJ, Park, BK, Choi, HS, Ahn, HS, Lee, JW , Yoo, KH , Sung, KW, Koo, HH, Kang, HJ, Park, KD, Shin, HY, Koh, KN, Im, HJ, Seo, JJ, Lim, YJ, Baek, HJ & Kook, H 2016, 'Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy', Pediatric Blood and Cancer, vol. 63, no. 9, pp. 1552-1556. https://doi.org/10.1002/pbc.26058

TY - JOUR

T1 - Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy

AU - Lee, Jun Ah

AU - Jeon, Dae Geun

AU - Cho, Wan Hyeong

AU - Song, Won Seok

AU - Yoon, Hoi Soo

AU - Park, Hyeon Jin

AU - Park, Byung Kiu

AU - Choi, Hyoung Soo

AU - Ahn, Hyo Seop

AU - Lee, Ji Won

AU - Yoo, Keon Hee

AU - Sung, Ki Woong

AU - Koo, Hong Hoe

AU - Kang, Hyoung Jin

AU - Park, Kyung Duk

AU - Shin, Hee Young

AU - Koh, Kyung Nam

AU - Im, Ho Joon

AU - Seo, Jong Jin

AU - Lim, Yeon Jung

AU - Baek, Hee Jo

AU - Kook, Hoon

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background: Efficacy of gemcitabine and docetaxel (GEM + DOC) chemotherapy in patients with recurrent or refractory osteosarcoma was evaluated. Methods: Data of 53 patients from 9 institutions, who received GEM (675 or 900 mg/m2 on days 1 and 8) and DOC (100 mg/m2 on day 8), were retrospectively reviewed. Results: GEM + DOC was administered as adjuvant (n = 25) or palliative chemotherapy (n = 28). Patients received a median 3 courses (range, 1−10 courses). Objective response rate (CR + PR, where CR is complete response and PR is partial response) and disease control rate (CR+ PR + SD, where SD is stable disease) were 14.3% and 28.6%, respectively. Disease control rate was higher in patients receiving 900 mg/m2 GEM than in patients receiving 675 mg/m2 (50.0% vs. 12.5%, P = 0.03). Higher GEM dose was associated with better survival, both in adjuvant (1-year overall survival, 90.9 ± 8.7% vs. 38.5 ± 13.5%, P = 0.002) and palliative settings (50.0 ± 14.4% vs. 31.3 ± 11.6%, P = 0.04). Conclusions: Further studies are necessary to investigate the efficacy of more aggressive and higher doses of GEM + DOC chemotherapy in osteosarcoma.

AB - Background: Efficacy of gemcitabine and docetaxel (GEM + DOC) chemotherapy in patients with recurrent or refractory osteosarcoma was evaluated. Methods: Data of 53 patients from 9 institutions, who received GEM (675 or 900 mg/m2 on days 1 and 8) and DOC (100 mg/m2 on day 8), were retrospectively reviewed. Results: GEM + DOC was administered as adjuvant (n = 25) or palliative chemotherapy (n = 28). Patients received a median 3 courses (range, 1−10 courses). Objective response rate (CR + PR, where CR is complete response and PR is partial response) and disease control rate (CR+ PR + SD, where SD is stable disease) were 14.3% and 28.6%, respectively. Disease control rate was higher in patients receiving 900 mg/m2 GEM than in patients receiving 675 mg/m2 (50.0% vs. 12.5%, P = 0.03). Higher GEM dose was associated with better survival, both in adjuvant (1-year overall survival, 90.9 ± 8.7% vs. 38.5 ± 13.5%, P = 0.002) and palliative settings (50.0 ± 14.4% vs. 31.3 ± 11.6%, P = 0.04). Conclusions: Further studies are necessary to investigate the efficacy of more aggressive and higher doses of GEM + DOC chemotherapy in osteosarcoma.

KW - docetaxel

KW - gemcitabine

KW - osteosarcoma

KW - recurrent

KW - refractory

UR - https://www.scopus.com/pages/publications/84978718907

U2 - 10.1002/pbc.26058

DO - 10.1002/pbc.26058

M3 - Article

C2 - 27197055

AN - SCOPUS:84978718907

SN - 1545-5009

VL - 63

SP - 1552

EP - 1556

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 9

ER -

Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this